

WEEKLY PRODUCT FEATURE

ResveraSirt-HP®



Biotics Research Corporation • (800) 231 - 5777 6801 Biotics Research Drive
Rosenberg, TX 77471 • biotics@bioticsresearch.com

WPB 14/04

ResveraSirt-HP® is a specialized, high dose trans-Resveratrol formula developed to support vascular integrity and healthy aging. Resveratrol has been shown to impact a diverse array of biochemical and physiological actions, and offers promising potential in promoting optimal wellness. Resveratrol has also been shown to provide significant antioxidant protection, to be cardioprotective, to down-regulate proinflammatory mediators, and to stimulate Sirtuin enzymes. In mammals, the seven Sirtuin proteins impact DNA repair and recombination, cell survival and energy metabolism via selective gene expression. In studies, resveratrol has been shown to mimic caloric restriction, which in mammals has been shown to increase life expectancy by more than 30 percent! **ResveraSirt-HP®** was developed and formulated in cooperation with Dr. Mark Houston, Associate Clinical Professor of Medicine at Vanderbilt Medical School and Director of Hypertension Institute and Vascular Biology in Nashville, TN. Each capsule of **ResveraSirt-HP®** supplies 250 mg of purified Trans-Resveratrol, 250 mg of Trans-Resveratrol, which Biotics tests for levels of benzopyrene, a carcinogenic polycyclic aromatic hydrocarbon (Current GMPs do not require this testing) sometimes identified in unacceptable concentrations in trans-resveratrol. The ResveraSirt-HP formula is enhanced by the addition of quercetin and IP-6. Quercetin has demonstrated the ability to decrease resveratrol metabolism, allowing for a longer half-life, while IP-6 functions as a strong metal chelator, adding stability to the formula. As always, you can count on Biotics Research to offer superior nutritional products supplying “The Best of Science and Nature”.



Research Pertaining to Other Topics of Interest

Chondroitin and Glucosamine protect against Colorectal Cancer? An exploratory analysis conducted with the VITamins And Lifestyle (VITAL) study observed any use of chondroitin and glucosamine to be associated with reduced risk of colorectal cancer (CRC) after 5 years of follow-up. Participants include over 75,000 western Washington residents aged 50-76. Use of chondroitin and glucosamine was ascertained by questions about supplement use during the 10 year period prior to baseline. Persons reporting use of chondroitin and glucosamine on 4+ days per week for 3+ years had a 45% lower CRC risk than non-users. Interestingly, the use of glucosamine alone was not associated with CRC risk. Also, an inverse association was observed among those that were overweight or obese, but not among those that were underweight or of normal weight.

Kantor, ED et al. Use of glucosamine and chondroitin supplements and risk of colorectal cancer. Cancer Causes and Control. Mar 2013

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.